221 related articles for article (PubMed ID: 18650450)
1. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.
Iacobucci I; Lonetti A; Messa F; Cilloni D; Arruga F; Ottaviani E; Paolini S; Papayannidis C; Piccaluga PP; Giannoulia P; Soverini S; Amabile M; Poerio A; Saglio G; Pane F; Berton G; Baruzzi A; Vitale A; Chiaretti S; Perini G; Foà R; Baccarani M; Martinelli G
Blood; 2008 Nov; 112(9):3847-55. PubMed ID: 18650450
[TBL] [Abstract][Full Text] [Related]
2. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
3. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G
Haematologica; 2007 Mar; 92(3):401-4. PubMed ID: 17339191
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.
Klein F; Feldhahn N; Herzog S; Sprangers M; Mooster JL; Jumaa H; Müschen M
Oncogene; 2006 Feb; 25(7):1118-24. PubMed ID: 16205638
[TBL] [Abstract][Full Text] [Related]
5. Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia.
Sun L; Goodman PA; Wood CM; Crotty ML; Sensel M; Sather H; Navara C; Nachman J; Steinherz PG; Gaynon PS; Seibel N; Vassilev A; Juran BD; Reaman GH; Uckun FM
J Clin Oncol; 1999 Dec; 17(12):3753-66. PubMed ID: 10577847
[TBL] [Abstract][Full Text] [Related]
6. Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method.
Iacobucci I; Lonetti A; Cilloni D; Messa F; Ferrari A; Zuntini R; Ferrari S; Ottaviani E; Arruga F; Paolini S; Papayannidis C; Piccaluga PP; Soverini S; Saglio G; Pane F; Baruzzi A; Vignetti M; Berton G; Vitale A; Chiaretti S; Müschen M; Foà R; Baccarani M; Martinelli G
Haematologica; 2008 Dec; 93(12):1814-21. PubMed ID: 18838475
[TBL] [Abstract][Full Text] [Related]
7. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
8. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
10. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Jones D; Thomas D; Yin CC; O'Brien S; Cortes JE; Jabbour E; Breeden M; Giles FJ; Zhao W; Kantarjian HM
Cancer; 2008 Sep; 113(5):985-94. PubMed ID: 18615627
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
12. IK6 isoform with associated cytogenetic and molecular abnormalities in Chinese patients with Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Yao L; Cen J; Chen S; Shen H; Chen Y; He J; Chen Z
Leuk Lymphoma; 2013 Aug; 54(8):1626-32. PubMed ID: 23150929
[TBL] [Abstract][Full Text] [Related]
13. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
Hofmann WK; Komor M; Wassmann B; Jones LC; Gschaidmeier H; Hoelzer D; Koeffler HP; Ottmann OG
Blood; 2003 Jul; 102(2):659-61. PubMed ID: 12663457
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
Ottmann O; Dombret H; Martinelli G; Simonsson B; Guilhot F; Larson RA; Rege-Cambrin G; Radich J; Hochhaus A; Apanovitch AM; Gollerkeri A; Coutre S
Blood; 2007 Oct; 110(7):2309-15. PubMed ID: 17496201
[TBL] [Abstract][Full Text] [Related]
16. Expression of Ikaros isoform 6 in chinese children with acute lymphoblastic leukemia.
Zhou F; Mei H; Jin R; Li X; Chen X
J Pediatr Hematol Oncol; 2011 Aug; 33(6):429-32. PubMed ID: 21792038
[TBL] [Abstract][Full Text] [Related]
17. In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
Kawaguchi H; Taketani T; Hongo T; Park MJ; Koh K; Ida K; Kobayashi M; Takita J; Taki T; Yoshino H; Bessho F; Hayashi Y
Leuk Lymphoma; 2005 Feb; 46(2):273-6. PubMed ID: 15621812
[TBL] [Abstract][Full Text] [Related]
18. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.
van der Veer A; Zaliova M; Mottadelli F; De Lorenzo P; Te Kronnie G; Harrison CJ; Cavé H; Trka J; Saha V; Schrappe M; Pieters R; Biondi A; Valsecchi MG; Stanulla M; den Boer ML; Cazzaniga G
Blood; 2014 Mar; 123(11):1691-8. PubMed ID: 24366361
[TBL] [Abstract][Full Text] [Related]
19. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
[TBL] [Abstract][Full Text] [Related]
20. Huaier extract enhances the treatment efficacy of imatinib in Ik6
Qu P; Han J; Qiu Y; Yu H; Hao J; Jin R; Zhou F
Biomed Pharmacother; 2019 Sep; 117():109071. PubMed ID: 31202171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
